• レポートコード:TPM-NV174 • 出版社/出版日:Transparency Market Research / 2019年10月28日 • レポート形態:英文、PDF、224ページ • 納品方法:Eメール • 産業分類:製薬 |
Single User | ¥857,660 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,301,660 (USD8,795) | ▷ お問い合わせ |
Global Site License | ¥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、関節炎治療法の世界市場について調べ、関節炎治療法の世界市場規模、市場動向、市場シェア、市場環境、市場予測、種類別(関節リウマチ、変形性関節症、乾癬性関節炎、痛風、その他)分析、薬物クラス別(TNF阻害剤、インターロイキン阻害剤、NSAID、コルチコステロイド、キサンチンオキシダーゼ阻害剤、およびその他)分析、投与経路別(経口、非経口、および局所)分析、流通チャンネル別(病院薬局、小売薬局、オンライン薬局)分析、関連企業情報などをまとめました。 ・関節炎治療法の市場概要 ・関節炎治療法の市場動向 ・関節炎治療法の世界市場規模・予測 ・関節炎治療法市場:種類別(関節リウマチ、変形性関節症、乾癬性関節炎、痛風、その他) ・関節炎治療法市場:薬物クラス別(TNF阻害剤、インターロイキン阻害剤、NSAID、コルチコステロイド、キサンチンオキシダーゼ阻害剤、およびその他) ・関節炎治療法市場:薬物クラス別(TNF阻害剤、インターロイキン阻害剤、NSAID、コルチコステロイド、キサンチンオキシダーゼ阻害剤、およびその他) ・関節炎治療法市場:流通チャンネル別(病院薬局、小売薬局、オンライン薬局) ・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米) ・競争環境・関連企業分析 |
The arthritis therapeutics market, characterized by healthy growth, is witnessing numerous promising pipeline projects and new product launches in parallel to increasing awareness campaigns run by public and private organizations. The patent expiration of blockbuster drugs is putting more pressure on manufacturers to develop effective versions of these drugs, which is projected to pave the way for the advancements of biosimilar products.
According to the Centers for Disease Control and Prevention (CDC) data published in 2018, ~54 Mn adults in the U.S. have been diagnosed with arthritis, and the number will grow to ~78 Mn by 2040. In this fast-paced era, individuals can’t afford to reduce their range of motion, which pertinently entails that those residing in developed countries are massively partaking in the diagnosis and treatment of arthritis as compared to those in developing countries. In the future, as the success of health awareness campaigns increases in developing countries, manufacturers in the arthritis therapeutics market will scramble towards these countries to leverage the first mover’s advantage.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Arthritis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Arthritis Therapeutics Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key product/brand Analysis
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. Regulatory Scenario by Region/globally
6. Global Arthritis Therapeutics Market Analysis and Forecast, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
6.3.1. Rheumatoid Arthritis
6.3.2. Osteoarthritis
6.3.3. Psoriatic Arthritis
6.3.4. Gout
6.3.5. Others
6.4. Market Attractiveness By Type
7. Global Arthritis Therapeutics Market Analysis and Forecast, By Drug Class
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
7.3.1. TNF Inhibitors
7.3.2. Interleukin Inhibitors
7.3.3. NSAIDs
7.3.4. Corticosteroids
7.3.5. Xanthine Oxidase Inhibitors
7.3.6. Others
7.4. Market Attractiveness By Drug Class
8. Global Arthritis Therapeutics Market Analysis and Forecast, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Topical
8.4. Market Attractiveness By Route of Administration
9. Global Arthritis Therapeutics Market Analysis and Forecast, By Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness By Distribution Channel
10. Global Arthritis Therapeutics Market Analysis and Forecast, By Region
10.1. Key Findings
10.2. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Sub-region /Region
11. North America Arthritis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
11.2.1. Rheumatoid Arthritis
11.2.2. Osteoarthritis
11.2.3. Psoriatic Arthritis
11.2.4. Gout
11.2.5. Others
11.3. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
11.3.1. TNF Inhibitors
11.3.2. Interleukin Inhibitors
11.3.3. NSAIDs
11.3.4. Corticosteroids
11.3.5. Xanthine Oxidase Inhibitors
11.3.6. Others
11.4. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Topical
11.5. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.6.1. U.S.
11.6.2. Canada
11.7. North America Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Drug Class
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country/Sub-region
12. Europe Arthritis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
12.2.1. Rheumatoid Arthritis
12.2.2. Osteoarthritis
12.2.3. Psoriatic Arthritis
12.2.4. Gout
12.2.5. Others
12.3. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
12.3.1. TNF Inhibitors
12.3.2. Interleukin Inhibitors
12.3.3. NSAIDs
12.3.4. Corticosteroids
12.3.5. Xanthine Oxidase Inhibitors
12.3.6. Others
12.4. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Topical
12.5. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Drug Class
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Arthritis Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
13.2.1. Rheumatoid Arthritis
13.2.2. Osteoarthritis
13.2.3. Psoriatic Arthritis
13.2.4. Gout
13.2.5. Others
13.3. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
13.3.1. TNF Inhibitors
13.3.2. Interleukin Inhibitors
13.3.3. NSAIDs
13.3.4. Corticosteroids
13.3.5. Xanthine Oxidase Inhibitors
13.3.6. Others
13.4. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Topical
13.5. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region /Sub-region, 2017–2027
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Drug Class
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Arthritis Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
14.2.1. Rheumatoid Arthritis
14.2.2. Osteoarthritis
14.2.3. Psoriatic Arthritis
14.2.4. Gout
14.2.5. Others
14.3. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
14.3.1. TNF Inhibitors
14.3.2. Interleukin Inhibitors
14.3.3. NSAIDs
14.3.4. Corticosteroids
14.3.5. Xanthine Oxidase Inhibitors
14.3.6. Others
14.4. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Topical
14.5. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region /Sub-region, 2017–2027
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Drug Class
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Arthritis Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
15.2.1. Rheumatoid Arthritis
15.2.2. Osteoarthritis
15.2.3. Psoriatic Arthritis
15.2.4. Gout
15.2.5. Others
15.3. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
15.3.1. TNF Inhibitors
15.3.2. Interleukin Inhibitors
15.3.3. NSAIDs
15.3.4. Corticosteroids
15.3.5. Xanthine Oxidase Inhibitors
15.3.6. Others
15.4. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
15.4.1. Oral
15.4.2. Parenteral
15.4.3. Topical
15.5. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region , 2017–2027
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Market Attractiveness Analysis
15.7.1. By Type
15.7.2. By Drug Class
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Share Analysis By Company (2018)
16.2. Company Profiles
16.2.1. Novartis AG
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Financial Overview
16.2.1.3. Product Portfolio
16.2.1.4. Strategic Overview
16.2.1.5. SWOT Analysis
16.2.2. Eli Lilly and Company
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Financial Overview
16.2.2.3. Product Portfolio
16.2.2.4. Strategic Overview
16.2.2.5. SWOT Analysis
16.2.3. Amgen, Inc.
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Financial Overview
16.2.3.3. Product Portfolio
16.2.3.4. Strategic Overview
16.2.3.5. SWOT Analysis
16.2.4. Merck & Co., Inc.
16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.4.2. Financial Overview
16.2.4.3. Product Portfolio
16.2.4.4. Strategic Overview
16.2.4.5. SWOT Analysis
16.2.5. Bristol-Myers Squibb Company
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Financial Overview
16.2.5.3. Product Portfolio
16.2.5.4. Strategic Overview
16.2.5.5. SWOT Analysis
16.2.6. Pfizer, Inc.
16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.6.2. Financial Overview
16.2.6.3. Product Portfolio
16.2.6.4. Strategic Overview
16.2.6.5. SWOT Analysis
16.2.7. AbbVie, Inc.
16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.7.2. Financial Overview
16.2.7.3. Product Portfolio
16.2.7.4. Strategic Overview
16.2.7.5. SWOT Analysis
16.2.8. Janssen Global Services, LLC (Johnson & Johnson)
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Financial Overview
16.2.8.3. Product Portfolio
16.2.8.4. Strategic Overview
16.2.8.5. SWOT Analysis
16.2.9. F. Hoffmann-La Roche Ltd
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Financial Overview
16.2.9.3. Product Portfolio
16.2.9.4. Strategic Overview
16.2.9.5. SWOT Analysis
16.2.10. Sanofi
16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.10.2. Financial Overview
16.2.10.3. Product Portfolio
16.2.10.4. Strategic Overview
16.2.10.5. SWOT Analysis